Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Barriers and facilitators to advance care planning implementation for patients with neurodegenerative diseases among Indian physicians: a mixed-methods analysis.

BMC health services research·2026

Same author

Hemiballistic hemi-myoclonus in Subacute Sclerosing Pan encephalitis - A novel observation.

Parkinsonism & related disorders·2026

Same author

Fenofibrate as adjuvant therapy in persons with active epilepsy: A double-blind, randomized, placebo-controlled trial.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Same author

Altered AMPA receptor subunit configuration contributes to dysfunctional excitatory synaptic activity in BCNU rat-model of focal cortical dysplasia (FCD).

Brain research·2026

Same author

Therapeutic plasma exchange in Myelin oligodendrocyte glycoprotein associated disorders-an ambispective study.

Multiple sclerosis and related disorders·2026

Same author

Natural Course of Neuropsychological Functions in Chronic Non-Surgical Hypoparathyroidism on Conventional Therapy: 12 Years of Follow-Up.

Calcified tissue international·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Ketogenic diet in epileptic encephalopathies.

Suvasini Sharma¹, Manjari Tripathi

¹Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi 110001, India.

Epilepsy Research and Treatment

|August 13, 2013

Summary

The medically supervised ketogenic diet (high-fat, low-carbohydrate) effectively treats refractory epilepsy and various seizure types. This review focuses on its use in severe epilepsy syndromes like Ohtahara syndrome and Lennox-Gastaut syndrome.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Related Experiment Videos

Last Updated: May 8, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Area of Science:

Neurology
Dietary Medicine
Clinical Nutrition

Background:

Refractory epilepsy presents significant treatment challenges.
The ketogenic diet is a well-established therapy for drug-resistant epilepsy.
Epileptic encephalopathies are severe epilepsy syndromes often resistant to conventional treatments.

Purpose of the Study:

To review the efficacy of the ketogenic diet in specific epileptic encephalopathies.
To consolidate current understanding of ketogenic diet applications in severe pediatric epilepsy syndromes.
To highlight the role of the ketogenic diet as a therapeutic option for challenging epilepsy cases.

Main Methods:

Literature review of studies on ketogenic diet use in epileptic encephalopathies.
Analysis of clinical data and case reports.
Synthesis of evidence regarding treatment outcomes and tolerability.

Main Results:

The ketogenic diet has demonstrated effectiveness in reducing seizure frequency across multiple epilepsy syndromes.
Specific syndromes reviewed include Ohtahara syndrome, West syndrome, Dravet syndrome, epilepsy with myoclonic atonic seizures, and Lennox-Gastaut syndrome.
The diet's impact on seizure control and potential adjunctive benefits are discussed.

Conclusions:

The ketogenic diet is a valuable therapeutic strategy for managing refractory epilepsy, particularly in epileptic encephalopathies.
Further research may elucidate optimal protocols and long-term outcomes for ketogenic diet therapy in these severe conditions.
This review underscores the importance of the ketogenic diet in the multidisciplinary approach to epilepsy management.